









Markets
/
Stocks
/
nasdaq-absi
/

Absci Corp

ABSI

2.690USD

+0.140+5.49%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

343.45MMarket Cap

LossP/E TTM



Absci Corp

2.690

+0.140+5.49%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

132 / 506

Overall Ranking

247 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

8.127

Target Price

+218.71%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Absci Corporation is a data-first generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. The Company’s Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, its Integrated Drug Creation platform aims to engineer biologics. It is developing a diversified portfolio of programs with a focus on cytokine biology. It has three wholly owned internal pipeline programs focusing on cytokine biology, as well as several other undisclosed pipeline programs under evaluation. Its wholly owned pipeline programs include ABS-101, ABS-201, and ABS-301. The Company’s other pipeline programs include ABS-501 and additional drug creation programs.

Growing

The company is in a growing phase, with the latest annual income totaling USD 4.53M.

Fairly Valued

The company’s latest PE is -2.84, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 100.84M shares, decreasing 2.84% quarter-over-quarter.

Held by Catherine Wood

Star Investor Catherine Wood holds 10.05M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.61.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 5.85, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 593.00K, representing a year-over-year decrease of 53.31%, while its net profit experienced a year-over-year decrease of 23.51%.

Score

Industry at a Glance

Previous score

5.85

Change



Financials

6.98

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.03

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.57

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -2.69, which is -11.52% below the recent high of -2.38 and -35.12% above the recent low of -3.64.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 132/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 8.25, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Absci Corp is 8.00, with a high of 10.00 and a low of 5.89.

Score

Industry at a Glance

Previous score

8.25

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Buy

Current Rating

8.127

Target Price

+218.71%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Absci Corp

ABSI

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 6.57, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 2.85 and the support level at 2.28, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.57

Change

0.36

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.072

Neutral

RSI(14)

52.383

Neutral

STOCH(KDJ)(9,3,3)

54.680

Neutral

ATR(14)

0.182

High Vlolatility

CCI(14)

96.074

Neutral

Williams %R

35.088

Buy

TRIX(12,20)

-0.353

Sell

StochRSI(14)

90.442

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

2.622

Buy

MA10

2.574

Buy

MA20

2.528

Buy

MA50

2.781

Sell

MA100

2.795

Sell

MA200

3.101

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 69.96%, representing a quarter-over-quarter decrease of 10.97%. The largest institutional shareholder is Catherine Wood, holding a total of 10.05M shares, representing 6.72% of shares outstanding, with 6.64% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

18.39M

+36.07%

ARK Investment Management LLC

Star Investors

10.96M

+32.53%

McClain (Sean)

8.73M

+1.38%

Redmile Group, LLC

8.25M

BlackRock Institutional Trust Company, N.A.

6.25M

+5.50%

The Vanguard Group, Inc.

Star Investors

4.69M

-1.81%

Phoenix Ventures Partners II LP.

4.75M

-49.28%

Fred Alger Management, LLC

4.29M

-33.99%

Woodline Partners LP

1.39M

+32.88%

Geode Capital Management, L.L.C.

2.00M

+2.39%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.15, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 2.04. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.